IMMUTEP Ltd
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type other
SEC Category Accelerated filer
State of Incorporation Australia
Business Address LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, C3, NSW 2000
Mailing Address LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE, SYDNEY,, C3, NSW 2000
Phone 612 8315 7003
Fiscal Year End 0630
EIN 000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | February 10, 2026 | View on SEC |
| 6-K Foreign company current report | January 30, 2026 | View on SEC |
| 6-K Foreign company current report | December 23, 2025 | View on SEC |
| 6-K Foreign company current report | December 17, 2025 | View on SEC |
| 6-K Foreign company current report | December 9, 2025 | View on SEC |
| 6-K Foreign company current report | December 3, 2025 | View on SEC |
| 6-K Foreign company current report | November 14, 2025 | View on SEC |
| 6-K Foreign company current report | November 4, 2025 | View on SEC |
| 6-K Foreign company current report | October 30, 2025 | View on SEC |
| 20-F Foreign company annual report | October 24, 2025 | View on SEC |
Annual Reports
20-F October 24, 2025
- Positive early results in lung and breast cancer trials
- Partnered with Ridgeback Capital for funding and expertise
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.